Tesamorelin Dosage and Pharmacokinetics, As Studied

The short version

This page describes what tesamorelin dosage looked like inside the studies — not a how-to. Nearly every trial used the same regimen: 2 mg injected under the skin once a day. The molecule itself clears the blood fast (within roughly half an hour to an hour), yet the growth-hormone and IGF-1 response it triggers lasts long enough that once-a-day dosing made sense. Because the research-grade material is supplied for laboratory work and is not the approved drug, nothing here is a dosing recommendation for a person.

Tesamorelin Dosage in the Research Literature

Tesamorelin dosage across the published trials is remarkably consistent. The dose used in both pivotal Phase 3 trials, and the FDA-approved regimen, is 2 mg subcutaneously once daily ^[1][2]. That single regimen carries almost the entire efficacy record: the 26-week NEJM trial ^[1], the 52-week long-term program ^[2], the JAMA hepatic-fat RCT ^[3], and every arm pooled in the 2026 meta-analysis ^[14]. A 1 mg subcutaneous daily arm has been studied as a lower comparator — in a cognition trial in older adults and as an arm in a dedicated type-2-diabetes safety trial — but the 2 mg once-daily paradigm is the extensively characterized one ^[4]. A later reformulation uses a higher-concentration once-daily subcutaneous preparation; the deep evidence base sits on the original 2 mg once-daily design.

The framing here is deliberately research-context only. The literature reports "2 mg/day administered subcutaneously to HIV patients," not a recommendation for any reader. Research-grade tesamorelin is supplied for laboratory use and is not the approved finished drug product, so this site gives no human dosing instructions. The route is the determining constraint: subcutaneous abdominal injection is the only route studied in clinical trials and the only FDA-approved route ^[1]. There is no oral, sublingual, or transdermal route in the evidence base — a peptide of this size is not orally bioavailable, and the negative-keyword space around "oral tesamorelin" or "tesamorelin tablets" describes formulations that do not exist in the literature.

Reconstitution and Stability, As Documented

Tesamorelin is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before use, and the regulatory label specifies refrigerated storage with the reconstituted solution used within a defined window. The stability problem the molecule solves is enzymatic, not thermal: native GHRH is inactivated within minutes by DPP-IV, and tesamorelin's trans-3-hexenoic acid N-terminal modification is precisely the feature that blocks that cleavage and extends biological activity ^[7]. This is a documentation point, not a handling instruction — research-grade material lacks the purity and potency oversight of the approved product, and nothing here describes preparing it for administration to a person.

Tesamorelin Half-Life and Pharmacokinetics

Plasma exposure is short and clearance is rapid. A population pharmacokinetic analysis of tesamorelin (1-2 mg/day subcutaneously for 14 days) in HIV patients and healthy subjects estimated apparent plasma clearance at ~1,060 L/h, found the absorbed fraction ~13% higher on day 14 than day 1, and identified no clinically relevant demographic covariates affecting PK ^[6]. Secondary sources (the FDA label and Mayo Clinic) describe a terminal half-life on the order of ~26-38 minutes; preclinical work reports comparably brief plasma persistence.

The apparent paradox — a peptide that clears in minutes yet is dosed once daily — resolves at the downstream level. Tesamorelin's action is to trigger a pulse of endogenous growth hormone, and the resulting IGF-1 elevation persists across the dosing interval well after the parent peptide is gone ^[4][10]. That decoupling of parent-drug half-life from pharmacodynamic effect is what makes a once-daily subcutaneous regimen rational. The trans-3-hexenoic acid N-terminal modification is what buys even this much plasma time: it blocks the DPP-IV cleavage that inactivates native GHRH within minutes ^[7].

What Is the Half-Life of Tesamorelin?

Population PK modeling reported apparent plasma clearance of ~1,060 L/h with no clinically relevant demographic covariates ^[6]; secondary sources describe a terminal half-life on the order of ~26-38 minutes. Despite that rapid clearance, the downstream IGF-1 elevation it triggers persists across the dosing interval, which is why once-daily dosing was studied ^[4].

How Long Does Tesamorelin Stay in Your System?

Plasma exposure is short, with rapid clearance (~1,060 L/h apparent clearance) and the absorbed fraction ~13% higher by day 14 than day 1 ^[6]. The downstream GH/IGF-1 response outlasts the parent peptide, which is why a once-daily subcutaneous regimen was the one studied ^[4]. The parent molecule itself does not accumulate to any meaningful degree between daily doses.